From GlobeNewswire: 2025-05-13 06:03:00

Fennec Pharmaceuticals reported first-quarter 2025 total net revenues of $8.8 million, marking an 18% year-over-year increase. The growth is attributed to a refined sales strategy and enhanced patient support services. Their PEDMARQSI product is now available in Germany and the United Kingdom. The company is hosting a conference call today at 8:30 a.m. ET. Fennec’s financial results for the quarter include net product sales of $8.8 million, a decrease in selling and marketing expenses, and a cash position of $22.6 million as of March 31, 2025.

Fennec Pharmaceuticals is focused on PEDMARK, the first FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric cancer patients. The company recently reported positive momentum and growth across key accounts with their patient support program. The availability of PEDMARQSI in Europe marks a significant milestone in expanding access to these critical treatments. The company will be participating in upcoming investor conferences and events, including the ASCO 2025 Annual Meeting and the Annual General Meeting for shareholders on June 3, 2025.



Read more at GlobeNewswire: Fennec Pharmaceuticals Reports First Quarter 2025 Financial